Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[bhp1rtp]

Anatabine readily crosses the blood-brain barrier.

"Right now, 98 percent of small-molecule drugs and 100 percent of large-molecule drugs and antibodies can't get through the blood-brain barrier," said Chenghua Gu, associate professor of neurobiology at HMS and senior author of the study. "Less than 1 percent of pharmaceuticals even try to target the barrier, because we don't know what the targets are.

http://medicalxpress.com/news/2014-05-blood-brain-barrier.html

We have previously shown that anatabine does display certain anti-inflammatory properties and readily crosses the blood-brain barrier suggesting it could represent an important compound for mitigating neuro-inflammatory conditions

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0055392